Essex Bio-Technology Executes HKD0.26 Million On-Market Share Buyback, Boosting Treasury Stock to 0.12% of Issued Shares

Bulletin Express06-25 17:04

Essex Bio-Technology Limited reported that it repurchased 100,000 ordinary shares on 25 June 2026, paying an aggregate HKD0.26 million at prices ranging between HKD2.63 and HKD2.64 per share. The volume-weighted average repurchase price was approximately HKD2.64.

Following the transaction: • Issued shares outstanding (excluding treasury shares) declined marginally by 0.0177% to 566.33 million. • Treasury shares increased to 673,000, representing 0.12% of the issued share capital approved under the current buyback mandate. • Total issued share capital, including treasury shares, remained unchanged at 567.01 million shares.

The buyback falls under the mandate granted by shareholders on 26 May 2026, which authorises the company to repurchase up to 56.70 million shares. To date, Essex Bio-Technology has repurchased 673,000 shares under this authority, utilising 0.12% of the approved limit.

Under Hong Kong Stock Exchange listing rules, the company is subject to a 30-day moratorium on issuing new shares or transferring treasury shares, effective until 25 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143920686?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143920686","market":"hk","top_or_hot":-1,"title":"Essex Bio-Technology Executes HKD0.26 Million On-Market Share Buyback, Boosting Treasury Stock to 0.12% of Issued Shares","media":"Bulletin Express","content":"<p>Essex Bio-Technology Limited reported that it repurchased 100,000 ordinary shares on 25 June 2026, paying an aggregate HKD0.26 million at prices ranging between HKD2.63 and HKD2.64 per share. The volume-weighted average repurchase price was approximately HKD2.64.</p>\n<p>Following the transaction:\n• Issued shares outstanding (excluding treasury shares) declined marginally by 0.0177% to 566.33 million.  \n• Treasury shares increased to 673,000, representing 0.12% of the issued share capital approved under the current buyback mandate.  \n• Total issued share capital, including treasury shares, remained unchanged at 567.01 million shares.</p>\n<p>The buyback falls under the mandate granted by shareholders on 26 May 2026, which authorises the company to repurchase up to 56.70 million shares. To date, Essex Bio-Technology has repurchased 673,000 shares under this authority, utilising 0.12% of the approved limit.</p>\n<p>Under Hong Kong Stock Exchange listing rules, the company is subject to a 30-day moratorium on issuing new shares or transferring treasury shares, effective until 25 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Essex Bio-Technology Executes HKD0.26 Million On-Market Share Buyback, Boosting Treasury Stock to 0.12% of Issued Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEssex Bio-Technology Executes HKD0.26 Million On-Market Share Buyback, Boosting Treasury Stock to 0.12% of Issued Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-25 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Essex Bio-Technology Limited reported that it repurchased 100,000 ordinary shares on 25 June 2026, paying an aggregate HKD0.26 million at prices ranging between HKD2.63 and HKD2.64 per share. The volume-weighted average repurchase price was approximately HKD2.64.</p>\n<p>Following the transaction:\n• Issued shares outstanding (excluding treasury shares) declined marginally by 0.0177% to 566.33 million.  \n• Treasury shares increased to 673,000, representing 0.12% of the issued share capital approved under the current buyback mandate.  \n• Total issued share capital, including treasury shares, remained unchanged at 567.01 million shares.</p>\n<p>The buyback falls under the mandate granted by shareholders on 26 May 2026, which authorises the company to repurchase up to 56.70 million shares. To date, Essex Bio-Technology has repurchased 673,000 shares under this authority, utilising 0.12% of the approved limit.</p>\n<p>Under Hong Kong Stock Exchange listing rules, the company is subject to a 30-day moratorium on issuing new shares or transferring treasury shares, effective until 25 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"","article_id":"1143920686","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143920686","pubTimestamp":1782378297,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Essex Bio-Technology Limited reported that it repurchased 100,000 ordinary shares on 25 June 2026, paying an aggregate HKD0.26 million at prices ranging between HKD2.63 and HKD2.64 per share. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技"},"translate_title":"亿胜生物科技执行26万港元场内股份回购，将库存股增至已发行股份的0.12%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"Essex Bio-Technology Limited reported that it repurchased 100,000 ordinary shares on 25 June 2026, paying an aggregate HKD0.26 million at prices ranging between HKD2.63 and HKD2.64 per share. The volume-weighted average repurchase price was approximately HKD2.64.\nFollowing the transaction:\n• Issued shares outstanding (excluding treasury shares) declined marginally by 0.0177% to 566.33 million.  \n• Treasury shares increased to 673,000, representing 0.12% of the issued share capital approved under the current buyback mandate.  \n• Total issued share capital, including treasury shares, remained unchanged at 567.01 million shares.\nThe buyback falls under the mandate granted by shareholders on 26 May 2026, which authorises the company to repurchase up to 56.70 million shares. To date, Essex Bio-Technology has repurchased 673,000 shares under this authority, utilising 0.12% of the approved limit.\nUnder Hong Kong Stock Exchange listing rules, the company is subject to a 30-day moratorium on issuing new shares or transferring treasury shares, effective until 25 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143920686","isCrawlerRequest":true}